UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA
Clinical trials for UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for tough bile duct cancers
Disease control OngoingThis study tests whether adding the targeted drug binimetinib to standard chemotherapy (FOLFOX) can shrink tumors or help people with advanced bile duct or gallbladder cancer live longer. About 66 adults whose cancer has a specific genetic change (MAPK pathway mutation) and has w…
Matched conditions: UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:24 UTC
-
New combo shows promise for Tough-to-Treat bile duct cancer
Disease control OngoingThis study tests a new drug called pevonedistat, given alone or with standard chemotherapy (paclitaxel and carboplatin), in people with advanced bile duct cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors. About 40 adults who hav…
Matched conditions: UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 24, 2026 16:05 UTC